Despite groundbreaking innovations, biopharmaceutical companies have struggled to keep pace with capital markets, underscoring the importance of not only scientific innovation but also the need for efficient strategies to drive value growth.
- The Benefits And Risks Of An LLC Business Model In Biotech
- DPHARM 2024 Highlights ClinOps Innovations That Address Cost, Complexity, & Capabilities
- Annovis Bio: Against The Grain In Alzheimer's Disease
- New Leadership At The Cancer Research Institute
- A Supply-Chain Woman Of Iran
- Where Are They Now? Carisma Therapeutics
- Thriving On Ambiguity: What I've Learned Leading Rare Disease Teams
- Know Your Customer: Strategic Considerations for AI-Powered Provider Segmentation
COMPANIES TO WATCH
-
![Greg_Kunst]( "Companies To Watch: Aurion Biotech")
Companies To Watch: Aurion BiotechAurion Biotech is developing what could become the first allogeneic combination cell therapy for the treatment of corneal endothelial diseases.
-
![Mark Litton]( "Companies To Watch: Athira Pharma")
Athira Pharma is developing small molecule therapeutics for neurodegenerative diseases, including its lead candidate, fosgonimeton, for Alzheimer's disease.
-
![Charles Hugh-Jones]( "Companies To Watch: Volastra Therapeutics")
Volastra Therapeutics is a drug discovery and development leader in the emerging field of chromosomal instability, a phenomenon that can determine how certain solid tumor cancer cells replicate and grow.
-
![Nicolas Poirier_OSE Immunotherapeutics]( "Companies To Watch: OSE Immunotherapeutics")
OSE Immunotherapeutics is poised to begin a confirmatory and pivotal Phase 3 trial for a novel cancer vaccine targeting the second line in NSCLC, an area of acute unmet need.
WHERE ARE THEY NOW
-
![Steven Kelly_300CMYK]( "Where Are They Now? Carisma Therapeutics")
Where Are They Now? Carisma TherapeuticsIn three years, Carisma Therapeutics has gone public, entered a broad collaboration with Moderna, and ceased development of its original CAR-Macrophage candidate, in favor of CAR-Monocyte therapies. Carisma expects to release CT-0525 Phase 1 data by the end of 2024.
-
![Rachel Haurwitz]( "Where Are They Now? Caribou Biosciences")
Where Are They Now? Caribou BiosciencesCaribou Biosciences is gunning for a Phase 3 pivotal trial start in 2025 for lead candidate CB-010, after cutting its CAR-NK preclinical activities to focus exclusively on developing CB-010 and two additional allogeneic CAR-T therapies.
-
![Otsuka cover_Oct 2016]( "Where Are They Now? Otsuka")
Where Are They Now? OtsukaOtsuka Precision Health, a new subsidiary focused on digital therapeutics and other tech-enabled solutions for patients, is a continuation of the company's broader mission described by an Otsuka executive in the pages of Life Science Leader eight years ago.
NEWSLETTER ARCHIVE
- 10.17.24 -- Resources For Trouble-Free Validation
- 10.17.24 -- Transform Clinical Data Review and Medical Review
- 10.16.24 -- AI, PoS, And ROI: An alphabet Soup Of 21st Century Drug Development
- 10.16.24 -- Overcoming The Challenges Of Your Life Science Venture
- 10.15.24 -- Curious About Diverse Antibodies?
SPOTLIGHT
From biochemist to executive supplier to angel investor to company founder and CEO, Maria Maccecchini, Ph.D.’s independent-minded approach to neurodegenerative disease could shake up the treatment landscape.
